REDONDO BEACH, CA–(Marketwired – Nov 7, 2016) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article taking a closer look at AXIM Biotechnologies’ (OTCQB: AXIM) cannabinoid-based clinical trials program.
AXIM is advancing their patented controlled-release cannabinoid gum in studies covering a number of indications. The company’s flagship CanChew Plus® contains 10mg of cannabidiol (CBD) procured from industrial hemp plants. Since the gum isn’t psychoactive, it is available in all 50 states without any prescription. The CanChew Plus® Irritable Bowel Syndrome (IBS) study will evaluate the concentration of CBD in the blood following the consumption of 10mg and 30mg CBD gum for thirty minutes. The data from this initial study will determine the appropriate dosing for patients in a subsequent Phase II clinical trial that will evaluate the safety and efficacy of CanChew Plus® gum in treating IBS symptoms and